肺癌性胸液GST—π含量测定及临床意义  

Determination of pleural nuld GST － π in patients with lung cancer and their clinical significance

作　　者：谢家印[1] 肖世全[1] 邹强[2] 张培炽[1] 

机构地区：[1]第三军医大学大坪医院肿瘤科,重庆400042 [2]第三军医大学免疫学教研室,重庆400038

出　　处：《癌症》1999年第2期203-204,207,共3页Chinese Journal of Cancer

摘　　要：目的：探讨肺癌性胸液GST－π含量与临床诊断和疗效关系。方法：采用BA－ELISA方法检测了279例肺癌患者（118例合并胸腔积液）血清和胸液GST－π含量。结果：118例肺癌患者（除15例小细胞肺癌患者外）血清及胸液GST－π含量明显高于健康人及胸肺良性病患者（p＜0．01），且胸液GST－π含量明显高于其血清水平（P＜0．01），肺癌患者胸液GST－π阳性率为65．2％，高于其血清水平（45．76％）。31例化疗有效的肺癌患者胸液GST－π水平明显低于72例化疗无效患者（29．97μg／L±7．78μg／L与34．01μg／L±g．98μg／L，P＜0．05）。结论：胸液GST－π测定不但可作为非小细胞肺癌的诊断标志物，而且对预测联合化疗疗效有一定指导作用。jective: TO assess the relation between the pleural nuid GST －π and the clinical diagnosis or therapeutic resPOne in patients with lung cancer. Methods: GST －π level in serum and pleural fluid of 279 patients with lung cancer (including 1 18 patients complicating with pleural effusion) was measured by asandwich enzyme－linked immunosorbent assay.Results: Serum or pleural fluid GST －π level in 1 18 Patients with lung cancer (except 15 patients with small cell lung careinoma) was higher than those of 30 healthy control subjects and 26 patients with benign pleuropulmonary disease (P <0. 01 ),and then the positive rate of pleural fluid GST －π (65. 2% ) in the lung cancer patients was higher than their serum GST －π (45.76% ), their GST －π ratio of pleural nuid to serum was more than 1. 46 in approximately 60. 17% of patients.Pleural fluid GST －πr bevel of 31 patients with non－small cell lung cancer responsing to chemotherapy was lower than those of yi nonresPOnders (29. 97μg/L ± 7. 78μg/L versus 34. 01 ±9.98μg/L t 9. 98μg/L, P <0.05) o Conclusion: The pleural fluid GST －π level may be a useful marker in the diagnosis Of lung cancer, and then it may be a parameter for predicting theraPeutic reslx,nse to combination chemotherapy regimens.

关 键 词：肺肿瘤 胸膜积液 GST-Π 诊断 

分 类 号：R734.204[医药卫生—肿瘤] R442.5[医药卫生—临床医学]